The FDA has approved tavapadon for adults with Parkinson's disease, and AbbVie will sell it as JUVMO. The company announced the decision on Sept. 28 and said the drug will reach patients in the United States in October.
Two features of the approval are unusual enough to state plainly. It is the first selective D1/D5 receptor agonist cleared for Parkinson's disease, which ends a long run in which the dopamine agonists in this class all worked through D2 and D3 receptors. And it is the first asset from AbbVie's $8.7 billion purchase of Cerevel Therapeutics to reach the market, which makes it the salvage of a deal whose most-hyped drug failed.
The motor data behind the approval are real and consistent across three Phase 3 trials. The tolerability claim the company has built its commercial pitch on has never been tested against the drugs it would displace, and the most recent independent look at the evidence says so in the plainest terms available: no trial used an active comparator, none ran past 27 weeks, and the proposed neuropsychiatric advantage over older agonists is, in the authors' own word, untested.
What was approved, and for whom
JUVMO is an oral tablet taken once a day, either on its own in early Parkinson's disease or alongside levodopa in patients whose symptoms fluctuate. It comes in 5 mg, 10 mg, and 15 mg strengths, with a separate titration pack containing 0.25 mg and 1 mg tablets to bring patients up to dose. AbbVie filed the application in September 2025.
More than 11 million people worldwide live with Parkinson's disease, and the drug's commercial case rests on a treatment problem that has been stable for decades. Oral levodopa remains the foundation of therapy and controls symptoms well, but its effect narrows over time and patients need higher and more frequent doses. In AbbVie's telling, about 70 percent of people with Parkinson's have their levodopa dose increased within the first year of therapy, and those adjustments can bring on dyskinesia, the involuntary movements that mark later-stage disease.
Dopamine agonists were supposed to be the answer to that escalation. They reduce the need for levodopa, but the ones on the market target D2 and D3 receptors, and their use is limited by side effects. Tavapadon targets D1 and D5 instead, a distinction that matters because the D1 receptor is the one most directly tied to movement. The company calls the approval the first dopaminergic breakthrough for Parkinson's disease in decades, and on the mechanism it has a fair claim.
The motor data are the strong part
The approval rests on the TEMPO program. TEMPO-1 and TEMPO-2 enrolled people with early Parkinson's disease who were not yet on levodopa. TEMPO-3 tested the drug as an add-on in patients whose symptoms already fluctuated on levodopa. TEMPO-4 is the open-label extension.
The results moved the same direction each time. In TEMPO-1 at week 26, the combined activities of daily living and motor score (MDS-UPDRS Parts II and III) worsened by 1.8 points on placebo, improved by 9.7 points at 5 mg, and improved by 10.2 points at 15 mg. On the daily living subscore alone, patients on the drug improved 22 to 23 percent from baseline while the placebo group got 12 percent worse. TEMPO-2, the flexible-dose trial, produced the number clinicians will quote: an average improvement of 10.3 points on the combined score against 1.2 points on placebo.
In TEMPO-3, the add-on produced 1.7 additional hours of good "on" time per day against 0.6 hours for placebo, and cut "off" time by 1.9 hours against 0.9 hours. Those are the numbers that matter to people whose medication stops working in the afternoon.
An independent systematic review published in August pooled seven randomized trials of selective D1/D5 agonists and reached the same conclusion with a slightly smaller effect: about 10.6 points of improvement on the combined score in early disease and roughly 1.1 additional hours of "on" time in levodopa-treated patients. The reviewers rated that motor benefit at moderate certainty, which is a real endorsement. Then they looked at everything else.
Thirty-eight percent did not finish
The TEMPO-2 publication carries a number that the press release does not lead with. Of 304 participants, 80 discontinued from the trial, and the imbalance between arms is stark: 57 of 151 on tavapadon, or 38 percent, against 23 of 153 on placebo, or 15 percent. Most of those exits were side effects. Thirty-six patients in the tavapadon arm, 24 percent of it, stopped because of an adverse event, compared with six patients, 4 percent, on placebo.
The specific complaints follow from that. Nausea affected 30 percent of patients on the drug and 3 percent on placebo. Headache hit 17 percent against 5 percent, and dizziness 16 percent against 3 percent. Nearly all of it clustered in the titration phase, when the dose is climbing, which suggests some of it resolves at a maintenance dose. A quarter of the tavapadon arm left anyway, and a trial that loses more than a third of one arm has limits on what it can say about tolerability over years.
That is the record a prescribing physician will weigh, because the trial population is the easiest possible one. TEMPO-2 enrolled people under 80 with less than three years of disease who had never taken a dopaminergic drug or had taken one for under three months. These are patients with the most tolerance for a rough first month and the most to gain from delaying levodopa. If 38 percent of them stopped, the number in a general neurology practice will not be lower.
The one claim no trial has tested
AbbVie's commercial argument, made by chief commercial officer Jeffrey Stewart on the company's July earnings call, is that tavapadon is less likely to cause sedation, the "sleep attacks" that have long shadowed D2/D3 agonists, and that there is "nothing else like it in the marketplace." The mechanism gives the claim a plausible basis, since the D1/D5 receptors are not where the sedation and impulse-control problems of the older drugs are concentrated.
Plausible is where it stands. The meta-analysis looked at impulse control disorder and found nine events in a single trial, an estimate so imprecise that the reviewers rated it very low certainty. Somnolence came out at very low certainty as well, and no outcome in the entire analysis reached high certainty. The reviewers' sentence is the one to remember: the proposed neuropsychiatric advantage over D2/D3 agonists remains untested, because no trial used an active comparator.
The approved label reflects that gap. It carries the class warnings for orthostatic hypotension, hallucinations, dyskinesia, and impulse-control behaviors that include compulsive gambling, eating, and shopping. A drug whose advantage was shown would not need those lines. A drug whose advantage is expected keeps them.
One more asymmetry is worth recording. The pooled analysis found adverse events overall were more common with tavapadon, at a risk ratio of 1.36, and that discontinuation because of an adverse event was 2.7 times more likely than on placebo. Serious adverse events were not increased, which is the reassuring half of that finding. The drug does not appear dangerous. It does appear to be something a substantial minority of patients cannot stay on.
What the 93 percent measures
The figure AbbVie puts highest in the release is about levodopa. After 85 weeks, 93 percent of patients taking tavapadon with levodopa had not increased their levodopa dose, and 94 percent of those taking it alone had not started levodopa. Against a background where most patients escalate within the first year, that is a meaningful difference.
It is also a figure from the open-label extension, where every patient knows they are on the drug and there is no placebo arm. Participants who could not tolerate tavapadon had already left the parent trials, so TEMPO-4 began with the survivors. Persistence in an extension study measures staying power among people who chose to keep going, and it should not be read as evidence that the drug changes the disease. Nothing in the TEMPO program tested whether tavapadon slows Parkinson's progression, and no approved therapy does.
The distinction matters for how the drug gets used. A treatment that delays levodopa escalation for two years changes when a patient meets dyskinesia, which is a quality-of-life argument and a real one. It does not change what the disease is doing underneath.
What the launch will decide
AbbVie has not disclosed a price. BioSpace reported that the company did not respond to questions on pricing and launch plans before publication, and analysts quoted in the trade press expect a gradual launch as coverage is negotiated. That negotiation runs through Medicare Part D, which covers the largest share of Parkinson's patients. The fight over Part D pharmacy contract standards is the machinery that decides it: formulary placement and prior authorization determine whether a new oral drug is reachable or sits behind a step therapy requirement that sends patients to a generic agonist first.
The clinical questions are narrower. Does the nausea and dizziness seen in trials settle into something manageable outside a protocol that requires monthly visits? Does the mechanism hold up in patients who are older and further along than the trial population? Does anyone run the comparison that would settle the tolerability argument, or does the field keep accepting a mechanism as a proxy for a result?
Parkinson's disease has been a hard target for a long time. Biogen and Denali discontinued an investigational therapy after it failed to slow progression in a Phase 2b study, and BioVie's mid-stage readout sent its shares down by half. Those failures were attempts to modify the disease, which tavapadon does not attempt. It improves symptoms through a new receptor, on data that show it working better than placebo and stopping more than a third of patients from continuing. That is enough for an approval and a real addition to the options list. It is not yet the breakthrough the release describes.
Primary sources
- AbbVie, U.S. FDA Approves AbbVie's JUVMO (tavapadon) for Parkinson's Disease, Sept. 28, 2026, for the approval, the TEMPO-1 and TEMPO-3 results, the 85-week extension data, the safety information, and the company's account of the mechanism.
- Fernandez HH, Bhatia P, Cloud L, et al. Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2). Lancet Neurol. 2026;25(8):721-730, for the TEMPO-2 enrollment, the primary endpoint, and the discontinuation and adverse-event rates.
- Rashid AA, Mohammad A, Malik U, et al. Efficacy, safety and certainty of evidence for selective D1/D5 dopamine receptor partial agonists in Parkinson's disease. Neurol Sci. 2026;47(9):708, for the pooled effect sizes, the adverse-event risk ratios, and the GRADE certainty ratings.
- Pahwa R, Moro E, Espay AJ, et al. Fixed-dose tavapadon for early Parkinson disease: a randomized clinical trial. JAMA Neurol. 2026;83(5):452-460, for the TEMPO-1 results.
- BioSpace, AbbVie wins FDA approval for Parkinson's drug from $8.7B Cerevel takeover, Sept. 28, 2026, for the Cerevel transaction history, the undisclosed pricing, and the market and sedation statements from the company's July earnings call.